JP2003518507A - 免疫系の活性化および阻害 - Google Patents

免疫系の活性化および阻害

Info

Publication number
JP2003518507A
JP2003518507A JP2001548135A JP2001548135A JP2003518507A JP 2003518507 A JP2003518507 A JP 2003518507A JP 2001548135 A JP2001548135 A JP 2001548135A JP 2001548135 A JP2001548135 A JP 2001548135A JP 2003518507 A JP2003518507 A JP 2003518507A
Authority
JP
Japan
Prior art keywords
inhibitor
inducer
cells
antigen
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001548135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003518507A5 (enExample
Inventor
フォクスウェル，ブライアン
フェルドマン，マーク
Original Assignee
シノヴィス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シノヴィス・リミテッド filed Critical シノヴィス・リミテッド
Publication of JP2003518507A publication Critical patent/JP2003518507A/ja
Publication of JP2003518507A5 publication Critical patent/JP2003518507A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/06—Uses of viruses as vector in vitro

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2001548135A 1999-12-24 2000-12-22 免疫系の活性化および阻害 Pending JP2003518507A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9930616.9 1999-12-24
GBGB9930616.9A GB9930616D0 (en) 1999-12-24 1999-12-24 Activation and inhibition of the immune system
PCT/GB2000/004925 WO2001047543A2 (en) 1999-12-24 2000-12-22 Activation and inhibition of the immune system

Publications (2)

Publication Number Publication Date
JP2003518507A true JP2003518507A (ja) 2003-06-10
JP2003518507A5 JP2003518507A5 (enExample) 2008-02-28

Family

ID=10867023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001548135A Pending JP2003518507A (ja) 1999-12-24 2000-12-22 免疫系の活性化および阻害

Country Status (12)

Country Link
US (2) US7915009B2 (enExample)
EP (2) EP1244466B1 (enExample)
JP (1) JP2003518507A (enExample)
CN (2) CN100563707C (enExample)
AT (1) ATE390929T1 (enExample)
AU (1) AU781496B2 (enExample)
CA (1) CA2394880A1 (enExample)
DE (1) DE60038503T2 (enExample)
ES (1) ES2302707T3 (enExample)
GB (1) GB9930616D0 (enExample)
NZ (1) NZ519438A (enExample)
WO (1) WO2001047543A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546775A (ja) * 2005-06-23 2008-12-25 ベイラー・カレツジ・オブ・メデイシン 負の免疫調節因子の変調及び免疫療法のための応用
JP2010505883A (ja) * 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
JP2016529916A (ja) * 2013-09-12 2016-09-29 アイカーン スクール オブ メディシン アット マウント サイナイ 蛍光タンパク質に特異的なｔ細胞受容体を有する遺伝子導入動物の作製方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
JP2004522432A (ja) * 2000-12-22 2004-07-29 シノヴィス・リミテッド Ｔｏｌｌ関連レセプター（ｔｒｒ）シグナル伝達の調節方法
GB0116249D0 (en) * 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods
JP2003055202A (ja) * 2001-08-15 2003-02-26 Hiroyuki Hanai 炎症性腸疾患の予防・治療剤
EP1512415A4 (en) * 2002-05-29 2005-11-09 Anges Mg Inc LURE COMPOSITION FOR TREATING AND PREVENTING INFLAMMATORY DISEASES
AU2002953094A0 (en) * 2002-12-04 2002-12-19 The University Of Queensland Immunomodulating compositions, processes for their production and uses therefor
WO2004027063A1 (en) * 2002-09-19 2004-04-01 Institut National De La Sante Et De La Recherche Medicale-Inserm Use of sirnas for gene silencing in antigen presenting cells
EP2557164A1 (en) * 2003-02-18 2013-02-13 Kevin M. Slawin Induced activation in dendritic cells
JP2007515937A (ja) * 2003-05-08 2007-06-21 ベス イスラエル デアコネス メディカル センター インコーポレイティッド ＮＦ−κＢの調節機構
TWI487535B (zh) 2004-11-30 2015-06-11 Centocor Inc 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
US20080311552A1 (en) * 2005-09-20 2008-12-18 London Health Sciences Centre Research, Inc. Use of Sirnas in Organ Storage/Reperfusion Solutions
DK1945820T3 (da) 2005-10-27 2013-11-11 Janssen Biotech Inc Toll-lignende receptor-3-modulatorer, fremgangsmåder og anvendelser
CN101240271B (zh) * 2006-08-28 2012-08-29 长春华普生物技术有限公司 Toll样受体调节性寡核苷酸及其用途
EP2076272B1 (en) * 2006-10-19 2015-07-29 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
WO2008080195A1 (en) * 2006-12-29 2008-07-10 The University Of Queensland Compositions and methods for treating or preventing unwanted immune responses
DK2331680T3 (en) * 2008-09-22 2017-08-21 Baylor College Medicine Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
PT3366302T (pt) * 2011-07-18 2022-03-07 Univ Kentucky Res Found Proteção de células da degeneração induzida por rna alu e inibidores para proteger as células
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
KR20150131218A (ko) 2013-03-14 2015-11-24 벨리쿰 파마슈티컬스, 인크. T 세포 증식의 제어 방법
CA2912172A1 (en) 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
CN106132423B (zh) 2014-02-14 2020-07-31 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
WO2015187847A1 (en) * 2014-06-03 2015-12-10 Cure-It Lifesciences, Llc Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml)
JP6868554B2 (ja) 2014-09-02 2021-05-12 ベリカム ファーマシューティカルズ， インコーポレイテッド ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激
AU2015341481C1 (en) 2014-11-03 2021-09-16 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T cell receptors directed against Bob1 and uses thereof
AU2015360502A1 (en) 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US10420836B2 (en) 2015-10-08 2019-09-24 Emory University Methods of immunizing a subject and compositions related thereto
MX2021014679A (es) 2019-05-31 2022-04-06 Janssen Pharmaceutica Nv Inhibidores de molécula pequeña de quinasa inductora de nf-kb.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06209778A (ja) * 1992-09-23 1994-08-02 F Hoffmann La Roche Ag ＮＦ−κＢアンチセンスポリヌクレオチド
JPH1171278A (ja) * 1997-09-01 1999-03-16 Kanegafuchi Chem Ind Co Ltd 転写因子ＮＦ−κＢ活性化阻害剤
JP2002513552A (ja) * 1998-05-06 2002-05-14 フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー ＮＦ−κＢ活性化の新規な阻害剤

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5149796A (en) 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
AU650249B2 (en) 1989-11-03 1994-06-16 Immulogic Pharmaceutical Corporation A human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
JP3418982B2 (ja) 1990-10-31 2003-06-23 ソマティクス セラピー コーポレイション 内皮細胞の遺伝的変性
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US5951988A (en) 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
ATE204300T1 (de) 1994-05-13 2001-09-15 Biovation Ltd Zielzellen-bindende chimäre peptide
CA2195642A1 (en) 1994-07-27 1996-02-08 Andreas Suhrbier Polyepitope vaccines
US5597898A (en) * 1995-02-15 1997-01-28 Yale University NF-κB activation regulatory protein, IκB-β
AU6181196A (en) 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal mast cell stabilizers
EP0779361A3 (en) * 1995-12-15 1999-11-10 F. Hoffmann-La Roche Ag Truncated form of inhibitory kappa B protein (1kB), recombinant production and uses thereof
UA71889C2 (uk) * 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
AU729247B2 (en) * 1996-08-12 2001-01-25 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
JP4695735B2 (ja) * 1996-08-26 2011-06-08 シグナル ファーマシューティカルズ， エルエルシー 刺激誘導性Ｉ（κ）Ｂキナーゼ［ＩＫＫ］シグナルソーム
US5891924A (en) * 1996-09-26 1999-04-06 Research Development Foundation Curcumin (diferuloylmethane) inhibition of NFκB activation
WO1998028424A2 (en) * 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
US6924308B1 (en) * 1997-07-30 2005-08-02 Howard L. Elford Therapeutic process for inhibiting NF-κB
US5952483A (en) * 1997-07-31 1999-09-14 Smithkline Beecham Corporation Human IκB-β
EP0897009A3 (en) * 1997-08-04 1999-06-09 Smithkline Beecham Plc HKABY60 polypeptides
GB9719238D0 (en) 1997-09-11 1997-11-12 Mathilda & Terence Kennedy Ins Viral infection of cells
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US5965421A (en) * 1997-11-26 1999-10-12 Human Genome Sciences, Inc. Human IRAK-2
EP1119618A2 (en) * 1998-02-19 2001-08-01 Peter Bromley Stress promoter control of therapeutic genes in gene therapy: compositions and methods
HUP0102782A3 (en) * 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
CA2367692A1 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
JP2004522432A (ja) 2000-12-22 2004-07-29 シノヴィス・リミテッド Ｔｏｌｌ関連レセプター（ｔｒｒ）シグナル伝達の調節方法
GB0116249D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06209778A (ja) * 1992-09-23 1994-08-02 F Hoffmann La Roche Ag ＮＦ−κＢアンチセンスポリヌクレオチド
JPH1171278A (ja) * 1997-09-01 1999-03-16 Kanegafuchi Chem Ind Co Ltd 転写因子ＮＦ−κＢ活性化阻害剤
JP2002513552A (ja) * 1998-05-06 2002-05-14 フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー ＮＦ−κＢ活性化の新規な阻害剤

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546775A (ja) * 2005-06-23 2008-12-25 ベイラー・カレツジ・オブ・メデイシン 負の免疫調節因子の変調及び免疫療法のための応用
JP2010505883A (ja) * 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
JP2016529916A (ja) * 2013-09-12 2016-09-29 アイカーン スクール オブ メディシン アット マウント サイナイ 蛍光タンパク質に特異的なｔ細胞受容体を有する遺伝子導入動物の作製方法
JP2020039353A (ja) * 2013-09-12 2020-03-19 アイカーン スクール オブ メディシン アット マウント サイナイ 蛍光タンパク質に特異的なｔ細胞受容体を有する遺伝子導入動物の作製方法
US11044896B2 (en) 2013-09-12 2021-06-29 Icahn School Of Medicine At Mount Sinai T cell receptors that are specific to a fluorescent protein, transgenic animals and methods of their making, isolated T cells, and methods of use

Also Published As

Publication number Publication date
EP1244466B1 (en) 2008-04-02
US7915009B2 (en) 2011-03-29
US20030153518A1 (en) 2003-08-14
DE60038503T2 (de) 2009-04-30
CN100563707C (zh) 2009-12-02
EP1852123A3 (en) 2008-09-10
CA2394880A1 (en) 2001-07-05
ATE390929T1 (de) 2008-04-15
US20080124322A1 (en) 2008-05-29
ES2302707T3 (es) 2008-08-01
WO2001047543A2 (en) 2001-07-05
CN1254272C (zh) 2006-05-03
WO2001047543A3 (en) 2002-01-17
CN1434718A (zh) 2003-08-06
CN1817367A (zh) 2006-08-16
EP1244466A2 (en) 2002-10-02
AU2206201A (en) 2001-07-09
DE60038503D1 (de) 2008-05-15
AU781496B2 (en) 2005-05-26
NZ519438A (en) 2004-03-26
GB9930616D0 (en) 2000-02-16
EP1852123A2 (en) 2007-11-07

Similar Documents

Publication Publication Date Title
US7915009B2 (en) Activation and inhibition of the immune system
Ashley et al. Bone marrow–generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
JP6697562B2 (ja) 樹状細胞組成物
US20080311140A1 (en) Antigen specific immunosuppression by dendritic cell therapy
WO2001085207A2 (en) Modulation of antigen processing using phagocytic cells
CN108289909A (zh) 用于产生工程改造的人原代血液树突细胞系的方法
JP2018531022A6 (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
US20140219979A1 (en) Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
WO2020145222A1 (ja) 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬
US7651857B2 (en) Methods for enhancing antigen presentation
EP0964697B1 (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
US20040241152A1 (en) Methods for inducing an immune response with an elevated th1/th2 ratio, by intracellular induction of nfkappab
US20030072743A1 (en) Genetic manipulation of phagocytes for modulation of antigen processing and the immune response therefrom
US20130337001A1 (en) Immunogenic composition for treatment of hepatitis C, a method for preparing the composition and use thereof for treating hepatitis C
Okada Cell delivery system: a novel strategy to improve the efficacy of cancer immunotherapy by manipulation of immune cell trafficking and biodistribution
Dissanayake Investigating the factors that govern the induction of an in vivo cytotoxic T-lymphocyte response against a tissue-borne antigen
WO2007025554A1 (en) Method for the generation of antigen-specific t-cells and uses thereof
Liu NanoAPC deliver antigen, IL-2 and co-stimulatory molecules to antigen specific T cells and activate viral specific T cells in chronic infections
AU2002314374A1 (en) Methods for inducing an immune response with an elevated TH1/TH2 ratio by intracellular induction of NFKAPPAB

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110422